April 26th 2024
During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, discussed the intracranial efficacy of brigatinib from the ALTA-1L trial for patients with ALK+ non–small cell lung cancer in the first article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Frontline Treatment Considerations in Non-Small Cell Lung Cancer
February 26th 2014Although the current standard of care for advanced NSCLC remains platinum doublet chemotherapy, recent evidence suggests that most newly diagnosed patients may be candidates for targeted therapy as firstline treatment.
Read More
Ramucirumab/Docetaxel Combination Demonstrates Survival Benefit in NSCLC
February 20th 2014The second-line administration of ramucirumab in combination with docetaxel demonstrated a statistically significant improvement in overall survival (OS) and progression-free survival (PFS) compared with placebo plus docetaxel in patients with non-small cell lung cancer (NSCLC). The announcement was made Feb. 19 by Eli Lilly and Company, the company developing the agent.
Read More
MK-3475 to be Evaluated Across Wide Range of Cancers
February 7th 2014Merck announced the signing of three separate clinical collaboration agreements to evaluate the potential of MK-3475 across multiple tumor types. The agreements were signed through subsidiaries with Amgen Inc., Incyte Corporation, and Pfizer Inc.
Read More
FDA Grants Breakthrough Therapy Designation for Dabrafenib for NSCLC
January 14th 2014The FDA has granted a Breakthrough Therapy designation to dabrafenib for its potential as a treatment for patients with metastatic BRAF V600E mutation-positive NSCLC who have received at least one prior line of platinum-containing chemotherapy.
Read More
LDK378: A Promising Next-Generation ALK Inhibitor
January 8th 2014LDK378 is a highly selective and potent inhibitor of ALK, and has demonstrated preclinical antitumor activity against tumors with acquired crizotinib resistance. In a phase I trial, LDK378 induced tumor response in 70% of patients with crizotinib-resistant NSCLC.
Read More
Model Emerges for Targeting Oncogenes in NSCLC
December 3rd 2013Between 2007 and 2011, a collaboration among clinical oncologists, pathologists, and industry scientists led to the identification of a new molecularly defined subset of NSCLC, followed by the finding that crizotinib, then under development as a MET inhibitor, was an inhibitor of ALK.
Read More
MPDL3280A Induces Durable Responses in NSCLC, Other Cancers
November 21st 2013MPDL3280A produced durable responses in studies in patients with forms of locally advanced/metastatic cancers, including smokers with NSCLC who customarily have poorer responses to cancer therapies than nonsmokers.
Read More
Molecular Targets in Non-Small Cell Lung Cancer
November 15th 2013Today, the treatment options for non-small cell lung cancer (NSCLC) in the United States include targeted therapies aimed at angiogenesis (bevacizumab), EGFR mutations (erlotinib and afatinib), and ALK translocations (crizotinib).
Read More
Multidisciplinary Perspectives: Molecular Testing in NSCLC
November 15th 2013Testing for genetic abnormalities is important in NSCLC, both to ensure that as many patients as possible are benefit from approved therapies and to advance understanding of more targets that may be able to lead to future treatments.
Read More